Skip to content
  • Resources

Hemophilia Treatment Centers

Many people with bleeding disorders use the resources of their hemophilia treatment center (HTC). Individuals who go to hemophilia treatment centers will not only find state-of-the art medical care, but also benefit from an experienced, caring staff that takes time to develop comprehensive treatment care plans for patients and families. Local Hemophilia Treatment Centers:
  • Gulf States Hemophilia & Thrombophilia Center 7000 Fannin, Suite 750 Houston, TX 77030 Phone: 713-500-8360
  • Texas Children’s Hemophilia & Thrombosis Center 6701 Fannin Street Suite 1580 Houston, Texas 77030 Phone: 832-822-4362
  • Children’s Blood and Cancer Center of Central Texas – Dell Children’s Specialty Pavillion 4910 Mueller Blvd Ste 200 Austin, TX 78723 Phone: 512-628-1900
  • South Texas Hemophilia Treatment Center Gateway Medical Park
  • 8435 Wurzbach Road San Antonio, TX 78229 Phone: 210-332-0661

Assistance Programs

Your Social Worker at your Hemophilia Treatment Center can help you navigate resources for financial assistance. Please contact your Social Worker for a LSBDF Helping Hands referral application.

Hemophilia Assistance Program

Website- Hemophilia Assistance Program The Hemophilia Assistance Program helps Texans with hemophilia cover their medical bills. Assistance is provided with blood factor replacement products or reimbursement for health insurance premium payment. Who is eligible for services? HAP is available to anyone who
  • Lives in Texas
  • Is 18 or older
  • Has an income at or below 200 percent of federal poverty guidelines
  • Has a diagnosis of hemophilia from a licensed physician
  • Isn’t incarcerated or a ward of the state
  • Isn’t eligible for the Children with Special Health Care Needs Services Program, Medicaid or Medicare

PAN Foundation

https://www.panfoundation.org

News from HFA

  • Advocacy News: May 2024

    Word from Washington Federal Agencies CMS extends waiver flexibilities, reporting requirements for Medicaid “unwinding” redeterminations According to the latest KFF Medicaid Unwinding Enrollment Tracker,  nearly 23 million Americans have lost Medicaid coverage since states were allowed to resume eligibility verifications following the COVID-19 public health emergency (PHE). Nearly 70 percent of Medicaid terminations continue to The post Advocacy News: May 2024 appeared first on Hemophilia Federation of America.

  • Leading Advocacy Organizations Celebrate Federal Rule Strengthening Protections Against Disability Discrimination 

    The Bleeding Disorders Substance Use and Mental Health Access Coalition (BD SUMHAC), National Bleeding Disorder Foundation (NBDF) and Hemophilia Federation of America (HFA) are pleased to share that after advocacy from the bleeding disorders community, the U.S. Department of Health and Human Services (HHS), through its Office for Civil Rights (OCR), finalized a new rule The post Leading Advocacy Organizations Celebrate Federal Rule Strengthening Protections Against Disability Discrimination  appeared first on Hemophilia Federation of America.

  • Advocacy News: April 2024

    Word from Washington After one year, Medicaid coverage losses during “unwinding” continue to surpass worst fears According to the latest KFF Medicaid Unwinding Enrollment Tracker, more than 21 millionAmericans have lost Medicaid coverage during the first year after states were allowed to resume eligibility verifications following the COVID-19 public health emergency. There remains wide variation The post Advocacy News: April 2024 appeared first on Hemophilia Federation of America.

  • May is Hepatitis Awareness Month

    In 2001, the Centers for Disease Control and Prevention designated the month of May as Hepatitis Awareness Month to bring awareness and attention to those living with viral hepatitis. In the 1980s and ’90s, thousands of people with hemophilia contracted HIV and hepatitis C (HCV) from the contaminated blood supply transmitted by clotting factor products. The post May is Hepatitis Awareness Month appeared first on Hemophilia Federation of America.

  • FDA Approves One-Time Gene Therapy for Adults with Hemophilia B

    From Pfizer: Pfizer Inc. announced that the US Food and Drug Administration has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing The post FDA Approves One-Time Gene Therapy for Adults with Hemophilia B appeared first on Hemophilia Federation of America.